Clinical Trials Browser

Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Azacitidine × 90 days × Clear all

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis